Skip to content
Search

Latest Stories

Boohoo drops DaBaby over HIV comments, rapper apologises

Boohoo drops DaBaby over HIV comments, rapper apologises

AFTER being dropped by British online fashion retailer Boohoo, American rapper DaBaby apologised for the comments he made about people with HIV while onstage at a US music festival.

He tweeted that his comments were "insensitive" adding he had "no intentions [of] offending anybody" before offering "my apologies".


The rapper had a clothing deal with Boohoo Group’s menswear fascia BoohooMAN.

It comes after Dua Lipa, whose song Levitating he features on, said she was "surprised and horrified" by his words.

"Anybody who done ever been [affected] by AIDS/HIV y'all got the right to be upset," DaBaby said.

He also addressed the LGBT community in his tweet saying "I ain't trippin on y'all, do you. y'all business is y'all business."

Performing at Rolling Loud festival in Miami on Sunday (25), DaBaby asked every audience member to "put your cell phone light up", apart from those who were HIV-positive or were gay men who had sex in car parks.

He also made the false claim that HIV will "make you die in two or three weeks".

After the event, DaBaby defended his comments in an Instagram story posted on Sunday (25), saying "What I do at the live show is for the audience at the live show. It would never translate correctly to someone looking a little five/six second clip."

The rapper faced massive backlash over his remarks about gay people and people living with HIV.

Boohoo on Wednesday (28), said in a statement "BoohooMAN condemn the use of homophobic language and confirm we will no longer be working with DaBaby.”

"Diversity and inclusion are part of the boohoo Groups DNA and we pride ourselves on representing the diverse customers we serve across the globe. We stand by and support the LGBTQ+ community, and do not tolerate any hate speech or discrimination in any form," it said.

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less